These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 25499605)

  • 1. Pharmacogenetic predictor of extrapyramidal symptoms induced by antipsychotics: multilocus interaction in the mTOR pathway.
    Mas S; Gassó P; Ritter MA; Malagelada C; Bernardo M; Lafuente A
    Eur Neuropsychopharmacol; 2015 Jan; 25(1):51-9. PubMed ID: 25499605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Network analysis of gene expression in peripheral blood identifies mTOR and NF-κB pathways involved in antipsychotic-induced extrapyramidal symptoms.
    Mas S; Gassó P; Parellada E; Bernardo M; Lafuente A
    Pharmacogenomics J; 2015 Oct; 15(5):452-60. PubMed ID: 25623440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetic study of antipsychotic induced acute extrapyramidal symptoms in a first episode psychosis cohort: role of dopamine, serotonin and glutamate candidate genes.
    Mas S; Gassó P; Lafuente A; Bioque M; Lobo A; Gonzàlez-Pinto A; Olmeda MS; Corripio I; Llerena A; Cabrera B; Saiz-Ruiz J; Bernardo M;
    Pharmacogenomics J; 2016 Oct; 16(5):439-45. PubMed ID: 27272046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Network analysis of gene expression in mice provides new evidence of involvement of the mTOR pathway in antipsychotic-induced extrapyramidal symptoms.
    Mas S; Gassó P; Boloc D; Rodriguez N; Mármol F; Sánchez J; Bernardo M; Lafuente A
    Pharmacogenomics J; 2016 Jun; 16(3):293-300. PubMed ID: 26122020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A common variant in DRD3 gene is associated with risperidone-induced extrapyramidal symptoms.
    Gassó P; Mas S; Bernardo M; Alvarez S; Parellada E; Lafuente A
    Pharmacogenomics J; 2009 Dec; 9(6):404-10. PubMed ID: 19506579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving pharmacogenetic prediction of extrapyramidal symptoms induced by antipsychotics.
    Boloc D; Gortat A; Cheng-Zhang JQ; García-Cerro S; Rodríguez N; Parellada M; Saiz-Ruiz J; Cuesta MJ; Gassó P; Lafuente A; Bernardo M; Mas S
    Transl Psychiatry; 2018 Dec; 8(1):276. PubMed ID: 30546092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Searching for functional SNPs or rare variants in exonic regions of DRD3 in risperidone-treated patients.
    Gassó P; Mas S; Oliveira C; Bioque M; Parellada E; Bernardo M; Trias G; Comeche J; Lafuente A
    Eur Neuropsychopharmacol; 2011 Apr; 21(4):294-9. PubMed ID: 20619616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identifying key transcription factors for pharmacogenetic studies of antipsychotics induced extrapyramidal symptoms.
    Boloc D; Rodríguez N; Torres T; García-Cerro S; Parellada M; Saiz-Ruiz J; Cuesta MJ; Bernardo M; Gassó P; Lafuente A; Mas S; Arnaiz JA
    Psychopharmacology (Berl); 2020 Jul; 237(7):2151-2159. PubMed ID: 32382784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopamine transporter (DAT) genotype (VNTR) and phenotype in extrapyramidal symptoms induced by antipsychotics.
    Lafuente A; Bernardo M; Mas S; Crescenti A; Aparici M; Gassó P; Catalan R; Mateos JJ; Lomeña F; Parellada E
    Schizophr Res; 2007 Feb; 90(1-3):115-22. PubMed ID: 17150335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extrapyramidal Symptoms During Risperidone Maintenance Treatment in Schizophrenia: A Prospective, Multicenter Study.
    Bo QJ; Li XB; Wang ZM; Li AN; Ma X; Wang CY
    J Clin Psychopharmacol; 2016 Apr; 36(2):125-9. PubMed ID: 26848792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Applicability of gene expression and systems biology to develop pharmacogenetic predictors; antipsychotic-induced extrapyramidal symptoms as an example.
    Mas S; Gassó P; Lafuente A
    Pharmacogenomics; 2015 Nov; 16(17):1975-88. PubMed ID: 26556470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pharmacogenetic-based risk assessment of antipsychotic-induced extrapyramidal symptoms].
    Kirnichnaya KA; Sosin DN; Ivanov MV; Mikhaylov VA; Ivashchenko DV; Ershov EE; Taraskina AE; Nasyrova RF; Krupitsky EM
    Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(4):113-125. PubMed ID: 26322366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The association study of polymorphisms in DAT, DRD2, and COMT genes and acute extrapyramidal adverse effects in male schizophrenic patients treated with haloperidol.
    Zivković M; Mihaljević-Peles A; Bozina N; Sagud M; Nikolac-Perkovic M; Vuksan-Cusa B; Muck-Seler D
    J Clin Psychopharmacol; 2013 Oct; 33(5):593-9. PubMed ID: 23963056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of extrapyramidal symptoms and tardive dyskinesia in schizophrenia: thirty-six-month results from the European schizophrenia outpatient health outcomes study.
    Novick D; Haro JM; Bertsch J; Haddad PM
    J Clin Psychopharmacol; 2010 Oct; 30(5):531-40. PubMed ID: 20814320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone.
    De Deyn PP; Katz IR; Brodaty H; Lyons B; Greenspan A; Burns A
    Clin Neurol Neurosurg; 2005 Oct; 107(6):497-508. PubMed ID: 15922506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenetic study on risperidone long-acting injection: influence of cytochrome P450 2D6 and pregnane X receptor on risperidone exposure and drug-induced side-effects.
    Choong E; Polari A; Kamdem RH; Gervasoni N; Spisla C; Jaquenoud Sirot E; Bickel GG; Bondolfi G; Conus P; Eap CB
    J Clin Psychopharmacol; 2013 Jun; 33(3):289-98. PubMed ID: 23609392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extrapyramidal symptoms and signs in first-episode, antipsychotic exposed and non-exposed patients with schizophrenia or related psychotic illness.
    Honer WG; Kopala LC; Rabinowitz J
    J Psychopharmacol; 2005 May; 19(3):277-85. PubMed ID: 15888513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyp2d6*3, *4, *5 and *6 polymorphisms and antipsychotic-induced extrapyramidal side-effects in patients receiving antipsychotic therapy.
    Crescenti A; Mas S; Gassó P; Parellada E; Bernardo M; Lafuente A
    Clin Exp Pharmacol Physiol; 2008 Jul; 35(7):807-11. PubMed ID: 18346175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risperidone treatment of behavioral disturbances in outpatients with dementia.
    Irizarry MC; Ghaemi SN; Lee-Cherry ER; Gomez-Isla T; Binetti G; Hyman BT; Growdon JH
    J Neuropsychiatry Clin Neurosci; 1999; 11(3):336-42. PubMed ID: 10440009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.